HomeCompareMYMD vs JNJ

MYMD vs JNJ: Dividend Comparison 2026

MYMD yields 110.50% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MYMD wins by $5.90M in total portfolio value
10 years
MYMD
MYMD
● Live price
110.50%
Share price
$1.81
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.93M
Annual income
$2,132,830.87
Full MYMD calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — MYMD vs JNJ

📍 MYMD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMYMDJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MYMD + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MYMD pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MYMD
Annual income on $10K today (after 15% tax)
$9,392.27/yr
After 10yr DRIP, annual income (after tax)
$1,812,906.24/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, MYMD beats the other by $1,808,920.25/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MYMD + JNJ for your $10,000?

MYMD: 50%JNJ: 50%
100% JNJ50/50100% MYMD
Portfolio after 10yr
$2.98M
Annual income
$1,068,760.14/yr
Blended yield
35.86%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

MYMD
No analyst data
Altman Z
-5.6
Piotroski
1/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MYMD buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMYMDJNJ
Forward yield110.50%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$5.93M$30.3K
Annual income after 10y$2,132,830.87$4,689.40
Total dividends collected$5.35M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MYMD vs JNJ ($10,000, DRIP)

YearMYMD PortfolioMYMD Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$21,750$11,049.72$10,592$272.30+$11.2KMYMD
2$45,733$22,460.60$11,289$357.73+$34.4KMYMD
3$93,072$44,137.91$12,123$472.89+$80.9KMYMD
4$183,537$83,949.70$13,141$629.86+$170.4KMYMD
5$351,102$154,717.47$14,408$846.81+$336.7KMYMD
6$652,287$276,608.54$16,021$1,151.60+$636.3KMYMD
7$1,178,220$480,272.57$18,122$1,588.22+$1.16MMYMD
8$2,071,454$810,758.34$20,930$2,228.20+$2.05MMYMD
9$3,548,616$1,332,160.25$24,792$3,191.91+$3.52MMYMD
10$5,929,850$2,132,830.87$30,274$4,689.40+$5.90MMYMD

MYMD vs JNJ: Complete Analysis 2026

MYMDStock

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

Full MYMD Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this MYMD vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MYMD vs SCHDMYMD vs JEPIMYMD vs OMYMD vs KOMYMD vs MAINMYMD vs ABBVMYMD vs MRKMYMD vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.